ATE439592T1 - Proteingerüste für antikörper-nachahmer und andere bindende proteine - Google Patents

Proteingerüste für antikörper-nachahmer und andere bindende proteine

Info

Publication number
ATE439592T1
ATE439592T1 AT99967261T AT99967261T ATE439592T1 AT E439592 T1 ATE439592 T1 AT E439592T1 AT 99967261 T AT99967261 T AT 99967261T AT 99967261 T AT99967261 T AT 99967261T AT E439592 T1 ATE439592 T1 AT E439592T1
Authority
AT
Austria
Prior art keywords
binding proteins
protein scaffolds
antibody mimics
proteins
disclosed
Prior art date
Application number
AT99967261T
Other languages
English (en)
Inventor
Dasa Lipovsek
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22340181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE439592(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE439592T1 publication Critical patent/ATE439592T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99967261T 1998-12-10 1999-12-09 Proteingerüste für antikörper-nachahmer und andere bindende proteine ATE439592T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11173798P 1998-12-10 1998-12-10
PCT/US1999/029317 WO2000034784A1 (en) 1998-12-10 1999-12-09 Protein scaffolds for antibody mimics and other binding proteins

Publications (1)

Publication Number Publication Date
ATE439592T1 true ATE439592T1 (de) 2009-08-15

Family

ID=22340181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99967261T ATE439592T1 (de) 1998-12-10 1999-12-09 Proteingerüste für antikörper-nachahmer und andere bindende proteine

Country Status (11)

Country Link
EP (2) EP2154535A1 (de)
JP (1) JP4562286B2 (de)
AT (1) ATE439592T1 (de)
AU (2) AU775076B2 (de)
CA (1) CA2351346C (de)
CY (1) CY1110549T1 (de)
DE (1) DE69941267D1 (de)
DK (1) DK1137941T4 (de)
ES (1) ES2329959T5 (de)
PT (1) PT1137941E (de)
WO (1) WO2000034784A1 (de)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
EP1250463B1 (de) 2000-01-24 2006-04-05 Compound Therapeutics, Inc. Sensible und multiplexe diagnostische tests zur proteinanalyse
CA2416219C (en) * 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
EP1332209B1 (de) 2000-09-08 2009-11-11 Universität Zürich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
CA2418835A1 (en) * 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
US7556925B2 (en) 2001-04-04 2009-07-07 University Of Rochester ανβ3 integrin-binding polypeptide monobodies and their use
EP1456410A2 (de) * 2001-12-11 2004-09-15 AlgoNomics N.V. Vefahren für die ausstellung von loops aus immunogloblin-domänen
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
US7083948B1 (en) 2002-12-24 2006-08-01 Immunex Corporation Polypeptide purification reagents and methods for their use
PT2829283T (pt) 2003-04-30 2017-09-08 Univ Zuerich Método para tratamento do cancro utilizando uma imunotoxina
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
KR101481844B1 (ko) 2006-03-27 2015-01-13 메디뮨 리미티드 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
KR20090058512A (ko) 2006-08-04 2009-06-09 아스트라제네카 아베 Ｅｒｂｂ2에 대한 인간 항체
ES2501947T3 (es) 2006-10-19 2014-10-02 Csl Limited Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
EP2111228B1 (de) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 Domain zur Behandlung von Krankheiten begleitet von unerwünschter Angiogenese
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
CA2682851C (en) 2007-04-02 2017-01-17 Philogen S.P.A. A novel antigen associated with the neovasculature of tumour metastases
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
EP2145021A2 (de) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarker und verfahren zur bestimmung der sensitivität gegenüber insulinwachstumsfaktor-1-rezeptormodulatoren
EA017995B1 (ru) 2007-07-25 2013-04-30 Филоджен С.П.А. Антиген, связанный с вариантами рака легкого и лимфомами
EP2209805B1 (de) 2007-10-30 2017-09-06 Philogen S.p.A. Mit rheumatoider arthritis assoziiertes antigen
EP2215246B1 (de) 2007-10-31 2015-01-07 MedImmune, LLC Proteingerüste
MX2010006735A (es) 2007-12-21 2010-09-30 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
AU2008345424A1 (en) * 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
EP2247615B1 (de) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Zielgerichtete therapeutika auf der basis von egfr gentechnisch hergestellten proteinen
CN102076713B (zh) * 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示系统
EP2379595A2 (de) 2008-12-23 2011-10-26 AstraZeneca AB Gegen a5b1 gerichtete gezielt bindende mittel und anwendungen davon
EP2379116B1 (de) 2009-01-07 2015-08-26 Philogen S.p.A. Mit endometriose assoziierte antigene
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
WO2011020033A2 (en) * 2009-08-13 2011-02-17 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
EP3279215B1 (de) 2009-11-24 2020-02-12 MedImmune Limited Gezielte bindemittel gegen b7-h1
AU2010334809C1 (en) 2009-12-23 2015-02-26 Agenus Inc. Binding members for human cytomegalovirus
WO2011127418A1 (en) 2010-04-09 2011-10-13 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
KR20130056870A (ko) 2010-04-13 2013-05-30 메디뮨 엘엘씨 피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드
HUE029622T2 (en) 2010-04-30 2017-03-28 Janssen Biotech Inc Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP3091028A1 (de) 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Auf fibronectin basierende gerüstproteine mit erhöhter stabilität
CA2809568C (en) 2010-09-01 2019-06-11 Genzyme Corporation Treatment of myocardial infarction using tgf - beta antagonists
BR112013015508B1 (pt) 2010-12-20 2022-04-05 Medimmune Limited Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
WO2012110824A1 (en) 2011-02-18 2012-08-23 Astrazeneca Ab Binding agents with specificity for a nucleic acid modification
EP3415528B1 (de) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc-fusionsproteine mit neuartigen linkern oder anordnungen
US9347058B2 (en) 2011-05-17 2016-05-24 Bristol-Myers Squibb Company Methods for the selection of binding proteins
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP2548891A1 (de) 2011-07-18 2013-01-23 Universiteit Maastricht Humaner monoklonaler Antikörper gegen die Gamma-Untereinheit des Acetylcholin-Rezeptors zur Verwendung bei der Behandlung von Rhabdomyosarkom
MX358827B (es) 2011-09-27 2018-09-05 Janssen Biotech Inc Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas.
CN103906767A (zh) 2011-10-10 2014-07-02 米迪缪尼有限公司 对类风湿关节炎的治疗
KR102434073B1 (ko) 2011-10-11 2022-08-18 비엘라 바이오, 인크. Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
US20140309229A1 (en) 2011-10-13 2014-10-16 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
PT2846836T (pt) 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
US20150166630A1 (en) 2012-07-19 2015-06-18 Amgen Inc. Btnl3 proteins, nucleic acids, and antibodies and uses thereof
RS58801B1 (sr) 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
EP2903629B1 (de) 2012-10-03 2019-07-10 Philogen S.p.A. Antikörperkonjugat zur verwendung bei der behandlung von entzündlichen darmerkrankungen
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014124017A1 (en) 2013-02-06 2014-08-14 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
CA2902789A1 (en) 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
GB201307501D0 (en) 2013-04-25 2013-06-12 Univ Aberdeen Anti-fungal antibody molecules and uses thereof
SG11201607818WA (en) 2014-03-20 2016-10-28 Bristol Myers Squibb Co Stabilized fibronectin based scaffold molecules
AU2015231170B2 (en) 2014-03-20 2019-10-03 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
SI3215530T1 (sl) 2014-11-07 2020-02-28 Sesen Bio, Inc. Izboljšana protitelesa IL-6
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
EP3353198B1 (de) 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3-bindende fibronektin-basierte gerüstmoleküle
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
ES3056995T3 (en) 2016-04-13 2026-02-25 Vivia Biotech Sl Ex vivo bite-activated t cells
CA3036564A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
KR102568559B1 (ko) 2016-12-14 2023-08-18 얀센 바이오테크 인코포레이티드 Cd8a-결합 섬유결합소 iii형 도메인
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
EP3612563A1 (de) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispezifische moleküle und verwendungen davon
EP4328241A3 (de) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispezifische moleküle mit einer nichtimmunglobulin-heterodimerisierungsdomäne und verwendungen davon
EP3630836A1 (de) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispezifische moleküle, die an myeloproliferatives leukämie (mlp)-protein binden, und deren verwendungen
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
EP3502139A1 (de) 2017-12-19 2019-06-26 Philogen S.p.A. Antikörper gegen tumorantigene
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
EP3765516A2 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunktionale moleküle und verwendungen davon
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
WO2020172598A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202109122SA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
EP4084821A4 (de) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. An cd33 bindende multifunktionsmoleküle und ihre verwendungen
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2021261420A1 (en) 2020-04-24 2022-12-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CA3190573A1 (en) 2020-08-26 2022-03-03 Andreas Loew Methods of detecting trbc1 or trbc2
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
JP2023539645A (ja) 2020-08-26 2023-09-15 マレンゴ・セラピューティクス，インコーポレーテッド Ｎｋｐ３０に結合する抗体分子およびその使用
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
JP2024531431A (ja) 2021-08-25 2024-08-29 イオンタス リミテッド 真核細胞で発現するタンパク質変異体のライブラリーの調製
EP4490187A4 (de) 2022-03-08 2026-02-25 Immunedge Inc Epo-rezeptor-agonisten und -antagonisten
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
KR20250093319A (ko) 2022-10-24 2025-06-24 에프. 호프만-라 로슈 아게 Il-6 길항제에 대한 반응 예측
US20260191905A1 (en) 2022-12-01 2026-07-09 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024251820A1 (en) 2023-06-06 2024-12-12 Iontas Limited Preparation of libraries of bispecific binders expressed in eukaryotic cells
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL131016A (en) * 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
JP3614866B2 (ja) * 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US11054998B1 (en) 2019-12-12 2021-07-06 Facebook, Inc. High bandwidth memory system with distributed request broadcasting masters

Also Published As

Publication number Publication date
ES2329959T3 (es) 2009-12-02
AU2004218675B2 (en) 2008-02-28
ES2329959T5 (es) 2013-12-18
JP2002532072A (ja) 2002-10-02
DK1137941T4 (da) 2014-01-06
CA2351346C (en) 2015-09-01
AU2357200A (en) 2000-06-26
WO2000034784A9 (en) 2000-11-16
DK1137941T3 (da) 2009-12-14
EP1137941B2 (de) 2013-09-11
DE69941267D1 (de) 2009-09-24
CA2351346A1 (en) 2000-06-15
EP1137941B1 (de) 2009-08-12
JP4562286B2 (ja) 2010-10-13
WO2000034784A1 (en) 2000-06-15
PT1137941E (pt) 2009-10-15
EP1137941A1 (de) 2001-10-04
EP2154535A1 (de) 2010-02-17
CY1110549T1 (el) 2015-04-29
AU775076B2 (en) 2004-07-15
EP1137941A4 (de) 2002-04-17
AU2004218675A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
CY1110549T1 (el) Ικριωματα πρωτεϊνων για μιμητικα αντισωματων και αλλες πρωτεϊνες συνδεσης
AU4185001A (en) Protein scaffolds for antibody mimics and other binding proteins
DE69813158D1 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
DK2233498T3 (da) Kallikrein-inhiberende Kunitz-domæneproteiner og nukleinsyrer, der koder for disse
ATE328896T1 (de) Faktor viii vom schwein und hybriden
ATE529509T1 (de) Selektion von proteinen unter verwendung von rna- protein-fusionen
ATE333094T1 (de) Verfahren zur herstellung von protein-beladenen mikropartikeln
ATE353138T1 (de) Verfahren zur stabilisierung und messung von troponinkomplexen
ATE394484T1 (de) Smad 6 und dessen anwendungen
DE69828341D1 (de) Maschine zur Prüfung von Werkstoffen
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
ATE220558T1 (de) Verbessertes verfahren zur stabilisierung von proteinen
DK0795605T3 (da) Denatureret lavdensitetslipoprotein-receptor
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DE69902796D1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
DE69831229D1 (de) Schnelle bestimmung des verhältnisses von biologischen molekülen
DE68917273D1 (de) Testmethode und Gerät zur Bestimmung des gesamten Proteins.
DE59706714D1 (de) Verfahren zur kodierung von sendungen
DE69738323D1 (de) Verfahren zur verringerung der abbaubarkeit von futterprotein
DE69828551D1 (de) Maschine zur Prüfung von Werkstoffen
DE69618536D1 (de) Verfahren zur Inaktivierung von Viren in Proteinen
ATE147861T1 (de) Funktioneller test zur bestimmung der protein s- aktivität
DE59105196D1 (de) Verfahren zur prüfung von anordnungen.
ATE385573T1 (de) Verfahren zum identifizieren von liganden der rna-polymerase sigma 70 untereinheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1137941

Country of ref document: EP